5-Amino-1MQ

NNMT Inhibitor | Longevity & Metabolic Enhancement

5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function. Originally developed for metabolic research, it's gaining attention for its potential anti-aging properties and ability to improve energy metabolism at the cellular level.

Daily dose

Oral: 50-100mg

Frequency

1x daily

Cycle length

4-12 weeks with mandatory breaks

Storage

Room temp (oral) / 2-8°C (injectable)

Key benefits

Enhanced NAD+ levels, improved mitochondrial function, potential longevity benefits, better energy metabolism, enhanced cellular repair mechanisms, improved insulin sensitivity

How it works

Inhibits NNMT enzyme, preventing NAD+ degradation and maintaining higher cellular NAD+ levels, which supports mitochondrial function, DNA repair, and metabolic processes essential for healthy aging

Dosage protocols

Goal

General longevity support

Dose

50mg · 1x daily

Route

Oral (with food)

Goal

Enhanced metabolic function

Dose

75mg · 1x daily

Route

Oral (with food)

Goal

Maximum NAD+ enhancement

Dose

100mg · 1x daily

Route

Oral (with food)

Goal

Conservative approach

Dose

25mg · 1x daily

Route

Oral (with food)

Research indications

longevity

NAD+ Enhancement — Significantly increases cellular NAD+ levels by inhibiting NNMT, supporting cellular energy production and DNA repair mechanisms

Mitochondrial Function — Improves mitochondrial biogenesis and efficiency, enhancing cellular energy production and reducing oxidative stress

Cellular Repair — Enhanced NAD+ availability supports sirtuins and other longevity pathways involved in DNA repair and cellular maintenance

metabolism

Energy Metabolism — Improves cellular energy production through enhanced mitochondrial function and more efficient glucose and fatty acid utilization

Insulin Sensitivity — May improve insulin sensitivity and glucose metabolism through enhanced cellular energy processes

Fat Oxidation — Potentially enhances fat burning and metabolic flexibility through improved mitochondrial function

weight Loss

Metabolic Enhancement — Increases basal metabolic rate and helps body burn fat for energy while maintaining muscle mass preferentially

Fat Cell Reduction — Mouse studies (PMC5826726) show 30% adipocyte size reduction at 60mg/kg/day

Energy Balance — Shifts body's energy balance toward burning fat rather than storing it, particularly beneficial for obesity

Administration

oral

injectable

Interactions

Synergistic

NAD+ Precursors (NMN, NR) — May work synergistically with NAD+ precursors by preventing breakdown while supporting production

Synergistic

Resveratrol — Both support longevity pathways; resveratrol activates sirtuins while 5-Amino-1MQ provides NAD+ substrate

Monitor Combination

Metformin — Both affect metabolic pathways; combination may enhance effects but requires careful monitoring

Compatible

BPC-157 — No known interactions; different mechanisms of action with potential complementary benefits

Unknown

Blood Thinners — Limited interaction data; consult healthcare provider before combining with anticoagulants

Monitor Combination

Berberine — Both affect metabolic pathways; potential additive effects on glucose metabolism

Safety notes

NO human clinical trials exist - all dosing from animal extrapolation

Injectable protocols differ by 100-200x (mcg vs mg) - verify units

Start with lowest effective dose (25-50mg oral) to assess tolerance

Take with food to reduce potential GI effects

Monitor for any unusual symptoms and discontinue if adverse effects occur

Not recommended for pregnant or breastfeeding women

Consult healthcare provider before use

Research studies

Muscle Function in Aged Mice (2024)

Animal study | 10mg/kg/day SubQ | 8 weeks

40% grip strength improvement in sedentary mice, 60% with exercise. No adverse effects observed.

View study →

Rat Pharmacokinetics Study (2021)

Animal PK study | Various doses | Bioavailability

Demonstrated 38.4% oral bioavailability, half-life 6.9hr (oral) and 3.8hr (IV). Supports oral administration viability.

View study →

Mouse Obesity Study - Neelakantan et al. (2018)

Animal study | 20mg/kg TID (60mg/kg/day) | 11 days | n=10 mice/group

Diet-induced obese mice showed 5.1% weight loss, 30% adipocyte size reduction. Human equivalent ~5mg/kg/day using FDA allometric scaling.

View study →

Related compounds

MOTS-c SS-31 (Elamipretide)NAD+SLU-PP-332